Oregovomab

Evans, Hannah C; Perry, Caroline M.

doi:10.2165/00024669-200302020-00005

Cited by 6 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although Evans added an appendix to Pothier's treatise on the subject, it was totally out of place there. 184 Even Pollock in full sail was unable to unseat it. 185 Attempts to undermine consideration by stealth using moral consideration also ended in failure.…”

Section: Legal Literature In the Early Nineteenth Centurymentioning

confidence: 99%

The classical model of contract: the product of a revolution in legal thought?

Swain

2010

Legal stud.

View full text Add to dashboard Cite

Writing in the introduction to his new treatise on contract in 1826, Joseph Chitty observed that ‘Perhaps no branch of the jurisprudence of this country has of late years been more subject of judicial inquiry and decision than the Law of Contracts’. It is generally accepted that the so‐called classical model of contract law, which remains influential into the present day, was created at this time. Ever since the subject first attracted sustained attention from legal historians in the 1970s, the driving forces of these developments have been contested. Some saw legal change as a product of economic and social factors. For others the reception of new ways of thinking and legal literature provided a more convincing explanation. What is not usually disputed is that there was a fundamental revolution in contract doctrine and literature in the nineteenth century. This assumption is open to challenge. It fails to give proper weight to the past. In fact these changes were deeply rooted in the eighteenth century and even earlier.

show abstract

Section: Legal Literature In the Early Nineteenth Centurymentioning

confidence: 99%

The classical model of contract: the product of a revolution in legal thought?

Swain

2010

Legal stud.

View full text Add to dashboard Cite

show abstract

CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients

Gordon

Schultes

Gallion

et al. 2004

Gynecologic Oncology

View full text Add to dashboard Cite

Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab

Berek¹

2004

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Recent advances in the molecular and cellular biology of malignancy and tumour immunology have stimulated significant progress in the application of immunotherapies as adjuvant treatments in cancer. Oregovomab (OvaRex, AltaRex) is a murine monoclonal antibody with high affinity to the ovarian cancer associated antigen CA125. Infusion of low-dose antibody results in formation of circulating immune complexes which can trigger a cellular immune response targeting CA125 and the ovarian cancer. Oregovomab has activity following initial chemotherapy and in recurrent disease settings and is in Phase III trials to establish its efficacy to prolong time to relapse in patients with advanced ovarian cancer and favourable outcomes to their front-line treatment. Additional studies of antigen processing and combination chemo-immunotherapy are ongoing. The treatment shows promise as a potential new addition to the standard care of ovarian cancer.

show abstract

Oregovomab

Cited by 6 publications

References 15 publications

The classical model of contract: the product of a revolution in legal thought?

The classical model of contract: the product of a revolution in legal thought?

CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients

Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab

Contact Info

Product

Resources

About